Drug interactions
Buprenorphine subdermal implant + Ipratropium-salbutamol
Severity: Minor
Buprenorphine subdermal implant and Ipratropium-salbutamol: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Buprenorphine has a modest QT-prolonging potential and high-dose salbutamol can cause hypokalemia and tachycardia. The combined risk of arrhythmia is generally small at usual doses.
What this interaction means in plain words
Buprenorphine subdermal implant and Ipratropium-salbutamol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Possible additive QT effects, with beta-2 agonist-induced hypokalemia as a contributing factor.
What to do
No routine action is needed; check potassium and consider an ECG if high-dose salbutamol is used or other QT-prolonging drugs or risk factors are present.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine subdermal implant and Ipratropium-salbutamol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipratropium-salbutamol
Frequently asked questions
Can I take Buprenorphine subdermal implant with Ipratropium-salbutamol?
MediHelp rates the interaction as minor. Buprenorphine subdermal implant and Ipratropium-salbutamol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Buprenorphine has a modest QT-prolonging potential and high-dose salbutamol can cause hypokalemia and tachycardia. The combined risk of arrhythmia is generally small at usual doses.
How serious is the interaction between Buprenorphine subdermal implant and Ipratropium-salbutamol?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine action is needed; check potassium and consider an ECG if high-dose salbutamol is used or other QT-prolonging drugs or risk factors are present.
What other medicines interact with Ipratropium-salbutamol?
MediHelp also lists interactions of Ipratropium-salbutamol with, for example, Amisulpride, Arsenic trioxide, Carvedilol. The full list is on the Ipratropium-salbutamol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
